Eric J. Lawitz MD FAASLD,AGAF,CPI

Hepatology & Liver Transplantation

Texas Liver Institute University of Texas Health San Antonio

607 Camden StSte 108San Antonio, TX 78215
Phone+1 210-253-3426
Fax+1 210-579-1252

Dr. Lawitz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lawitz's full profile Already have an account?

Summary

Eric Lawitz, MD, based in San Antonio, TX, is a gastroenterologist with subspecialties in hepatology. He completed his medical education at Rush Medical College in 1993 and his residency and fellowship at the San Antonio Uniformed Services Health Education Consortium. Dr. Lawitz has extensive experience in hepatology, focusing on conditions such as hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, primary biliary cholangitis, autoimmune hpeatitis, and cirrhosis. His research contributions include several published studies in notable journals like The Lancet and NEJM and has over 59,000 citations with a h-index of 101. Dr. Lawitz has been recognized as a Fellow by several esteemed organizations, including the American Association for the Study of Liver Diseases and the American Gastroenterological Association.

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Gastroenterology, 1996 - 1999
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1993 - 1996
Rush Medical College of Rush University Medical CenterClass of 1993

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TX State Medical License 2003 - 2026
WI State Medical License 1995 - 2003
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

FAASLD Fellow of the American Association for the Study of Liver Diseases, 2016
FAPCR Fellow of the Academy of Physicians in Clinical Research, 2016
Fellow (AGAF) American Gastroenterological Association, 2012

Clinical Trials

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
COMPLETED
PHASE1
TD-6450 MAD Study in HCV Infected Subjects
COMPLETED
PHASE1
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
COMPLETED
PHASE2

Publications & Presentations

PubMed

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: ...
Rohit Loomba, Jacob George, Laurent Castera, Sven Francque, Eric Lawitz
The Lancet. Gastroenterology & Hepatology. 2026-09-01
A First-in-Human study of AHB-137, an unconjugated antisense oligonucleotide, in healthy subjects and patients with chronic hepatitis B.
Edward J Gane, Yao-Chun Hsu, Chi-Yi Chen, Shyamasundaran Kottilil, Eric Lawitz
Hepatology. 2026-08-12
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Mazen Noureddin, Arun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, Corinna Schoelch
Hepatology. 2026-08-03

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet

Press Mentions

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025October 22nd, 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025May 1st, 2025
PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024